Neuronal ceroid lipofuscinoses

Epileptic Disorders

Volumn 18, Issue , 2016, Pages S73-S88

  Nita, Dragos A ^a   Mole, Sara E ^b   Minassian, Berge A ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Batten; Haltia Santavuori; Jansk Bielschowsky; progressive myoclonus epilepsies; Spielmeyer

Indexed keywords

MERCAPTAMINE; TRIPEPTIDYL PEPTIDASE I;

CEREBELLUM ATROPHY; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DISEASE CLASSIFICATION; ELECTRON MICROSCOPY; ENZYME ANALYSIS; ENZYME REPLACEMENT; GENE MUTATION; GENE THERAPY; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; IMMUNOMODULATION; MYOCLONUS EPILEPSY; NERVE DEGENERATION; NEURAL STEM CELL; NEURONAL CEROID LIPOFUSCINOSIS; NEUROPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETINOPATHY; REVIEW; STEM CELL TRANSPLANTATION; GENETICS; METABOLISM; NEURONAL CEROID-LIPOFUSCINOSES;

HUMANS; NEURONAL CEROID-LIPOFUSCINOSES;

EID: 84994112392     PISSN: 12949361     EISSN: 19506945     Source Type: Journal    
DOI: 10.1684/epd.2016.0844     Document Type: Review

References (80)

1. Ahtiainen L, Luiro K, Kauppi M, Tyynela J, Kopra O, Jalanko A. Palmitoyl protein thioesterase 1 (PPT1) deficiency causes endocytic defects connected to abnormal saposin processing. Exp Cell Res 2006; 312: 1540–1553.
2. Anderson G, Smith VV, Malone M, Sebire NJ. Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre. J Clin Pathol 2005; 58: 1305–1310.
3. Autti T, Raininko R, Launes J, Nuutila A, Santavuori P. Jansky-Bielschowsky variant disease: CT, MRI, and SPECT findings. Pediatr Neurol 1992; 8: 121–126.
4. Batten FE. Cerebral degeneration with symmetrical changes in the maculae in two members of a family. Trans Ophthalmol Soc UK 1903; 23: 386–390.
5. Bielschowsky M. Über spätinfantile familiäre amaurotische Idiotie mit Kleinhirnsymptonen. Dtsch Z Nervenheilkd 1913; 50: 7–29.
6. Bras J, Verloes A, Schneider SA, Mole SE, Guerreiro RJ. Mutation of the parkinsonism gene A2 causes neuronal ceroid-lipofuscinosis ATP13. Hum Mol Genet 2012; 21: 2646–2650.
7. Chang M, Cooper JD, Sleat DE, et al. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 2008; 16: 649–656.
8. Chattopadhyay S, Kriscenski-Perry E, Wenger DA, Pearce DA. An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses. Neurology 2002; 59: 1816–1817.
9. Craiu D, Dragostin O, Dica A, et al. Rett-like onset in late-infantile neuronal ceroid lipofuscinosis (CLN7) caused by compound heterozy ous mutation in the gene and review of the literature data on clinical onset signs MFSD8. Eur J Paediatr Neurol 2015; 19: 78–86.
10. Eksandh LB, Ponjavic VB, Munroe PB, et al. Full-field ERG in patients with Batten/Spielmeyer-Vogt disease caused by mutations in the gene CLN3. Ophthalmic Genet 2000; 21: 69–77.
11. Elleder M, Franc J, Kraus J, Nevsimalova S, Sixtova K, Zeman J. Neuronal ceroid lipofuscinosis in the Czech Republic: analysis of 57 cases. Report of the “Prague NCL group”. Eur J Paediatr Neurol 1997; 1: 109–114.
12. Goebel HH, Wisniewski KE. Current state of clinical and morphological features in human NCL. Brain Pathol 2004; 14: 61–69.
13. Golabek AA, Kida E, Walus M, Kaczmarski W, Michalewski M, Wisniewski KE. CLN3 protein regulates lysosomal pH, and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells. Mol Genet Metab 2000; 70: 203–213.
14. Greaves J, Chamberlain LH. Palmitoylation-dependent protein sorting. J Cell Biol 2007; 176: 249–254.
15. Guillaume DJ, Huhn SL, Selden NR, Steiner RD. Cellular therapy for childhood neurodegenerative disease. Part I: rationale and preclinical studies. Neurosurg Focus 2008; 24: E22.
16. Haltia M, Rapola J, Santavuori P. Infantile type of so-called neuronal ceroid-lipofuscinosis. Histological and electron microscopic studies. Acta Neuropathol 1973; 26: 157–170.
17. Haltia M, Rapola J, Santavuori P, Keranen A. Infantile type of so-called neuronal ceroid-lipofuscinosis 2. Morphological and biochemical studies. J Neurol Sci 1973; 18: 269–285.
18. Heine C, Koch B, Storch S, Kohlschutter A, Palmer DN, Braulke T. Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A. J Biol Chem 2004; 279: 22347–22352.
19. Hobert JA, Dawson G. A novel role of the Batten disease gene, association with BMP synthesis CLN3. Biochem Biophys Res Commun 2007; 358: 111–116.
20. Holopainen JM, Saarikoski J, Kinnunen PK, Jarvela I. Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur J Biochem 2001; 268: 5851–5856.
21. Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. Biochim Biophys Acta 2009; 1793: 697–709.
22. Janský J. Dosud nepopsaný pripad familiárniamaurotické idiotie komplikované s hypoplasii mozeckovou. Sb Lek 1908; 13: 165–196.
23. Kitzmuller C, Haines RL, Codlin S, Cutler DF, Mole SE. A function retained by the common mutant CLN3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosis. Hum Mol Genet 2008; 17: 303–312.
24. Kousi M, Siintola E, Dvorakova L, et al. Mutations in are a common cause of variant late-infantile neuronal ceroid lipofuscinosis CLN7/MFSD8. Brain 2009; 132: 810–819.
25. Kufs H. Über eine Spätform der amaurotischen Idiotie und ihre heredofamiliären Grundlagen. Z Gesamte Neurol Psychiatr 1925; 95: 168–188.
26. Kyttala A, Lahtinen U, Braulke T, Hofmann SL. Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins. Biochim Biophys Acta 2006; 1762: 920–933.
27. Lake BD, Hall NA. Immunolocalization studies of subunit c in late-infantile and juvenile Batten disease. J Inherit Metab Dis 1993; 16: 263–266.
28. Levin SW, Baker EH, Zein WM, et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol 2014; 13: 777–787.
29. Lu JY, Hofmann SL. Inefficient cleavage of palmitoyl-protein thioesterase (PPT) substrates by aminothiols: implications for treatment of infantile neuronal ceroid lipofuscinosis. J Inherit Metab Dis 2006; 29: 119–126.
30. Lu JY, Hu J, Hofmann SL. Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2010; 99: 374–378.
31. Margraf LR, Boriack RL, Routheut AA, et al. Tissue expression and subcellular localization of CLN3, the Batten disease protein. Mol Genet Metab 1999; 66: 283–289.
32. Marshall FJ, de Blieck EA, Mink JW, et al. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology 2005; 65: 275–279.
33. Minassian BA, Striano P, Avanzini G. Progressive Myoclonus Epilepsies: State-of-the-Art. Epileptic Disord 2016; 18(Suppl. 2): S1–S158.
34. Mink JW. Neuronal ceroid lipofuscinoses (Batten's disease). In: American Academy of Neurology Annual Meeting, 2010.
35. Mitchison HM, Hofmann SL, Becerra CH, et al. Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits. Hum Mol Genet 1998; 7: 291–297.
36. Mole SE. Development of new treatments for Batten disease. Lancet Neurol 2014; 13: 749–751.
37. Mole SE, Williams RE. Neuronal Ceroid-Lipofuscinoses. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, (Editors). GeneReviews® [Internet]. Seattle (WA). 2001 Oct 10 [updated 2013 Aug 1].
38. Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta 2015; 1852: 2237–2241.
39. Mole SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 2005; 6: 107–126.
40. Mole S, Williams R, Goebel H. The neuronal ceroid lipofuscinoses (Batten disease), 2nd ed. Oxford: Oxford University Press, 2011.
41. Munroe PB, Mitchison HM, O'Rawe AM, et al. Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet 1997; 61: 310–316.
42. Narayan SB, Rakheja D, Tan L, Pastor JV, Bennett MJ. CLN3 P the Batten's disease protein, is a novel palmitoyl-protein delta-9 desaturase. Ann Neurol 2006; 60: 570–577.
43. Passini MA, Dodge JC, Bu J, et al. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci 2006; 26: 1334–1342.
44. Pearce DA, Atkinson M, Tagle DA. Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology 2004; 63: 2001–2005.
45. Phillips SN, Benedict JW, Weimer JM, Pearce DA. CLN3, the protein associated with Batten disease: structure, function and localization. J Neurosci Res 2005; 79: 573–583.
46. Puranam KL, Guo WX, Qian WH, Nikbakht K, Boustany RM. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol Genet Metab 1999; 66: 294–308.
47. Ramadan H, Al-Din AS, Ismail A, et al. Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1. Neurology 2007; 68: 387–393.
48. Ramirez-Montealegre D, Pearce DA. Defective lysosomal arginine transport in juvenile Batten disease. Hum Mol Genet 2005; 14: 3759–3773.
49. Ranta S, Lehesjoki AE. Northern epilepsy, a new member of the NCL family. Neurol Sci 2000; 21: S43–S47.
50. Rawlings ND, Barrett AJ. Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis. Biochim Biophys Acta 1999; 1429: 496–500.
51. Riikonen R, Vanhanen SL, Tyynela J, Santavuori P, Turpeinen U. CSF insulin-like growth factor-1 in infantile neuronal ceroid lipofuscinosis. Neurology 2000; 54: 1828–1832.
52. Santavuori P, Haltia M, Rapola J, Raitta C. Infantile type of so-called neuronal ceroid-lipofuscinosis 1. A clinical study of 15 patients. J Neurol Sci 1973; 18: 257–267.
53. Santavuori P, Rapola J, Nuutila A, et al. The spectrum of Jansky-Bielschowsky disease. Neuropediatrics 1991; 22: 92–96.
54. Santavuori P, Lauronen L, Kirveskari K, Aberg L, Sainio K. Neuronal ceroid lipofuscinoses in childhood. Suppl Clin Neurophysiol 2000; 53: 443–451.
55. Schulz A, Dhar S, Rylova S, et al. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann Neurol 2004; 56: 342–350.
56. Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases – clinical perspectives. Biochim Biophys Acta 2013; 1832: 1801–1803.
57. Seitz D, Grodd W, Schwab A, Seeger U, Klose U, Nagele T. MR imaging and localized proton MR spectroscopy in late infantile neuronal ceroid lipofuscinosis. Am J Neuroradiol 1998; 19: 1373–1377.
58. Selden NR, Al-Uzri A, Huhn SL, et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr 2013; 11: 643–652.
59. Sharp JD, Wheeler RB, Parker KA, Gardiner RM, Williams RE, Mole SE. Spectrum of mutations in variant late infantile neuronal ceroid lipofuscinosis CLN6. Hum Mutat 2003; 22: 35–42.
60. Siintola E, Partanen S, Stromme P, et al. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 2006; 129: 1438–1445.
61. Sleat DE, Gin RM, Sohar I, et al. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet 1999; 64: 1511–1523.
62. Sleat DE, Lackland H, Wang Y, et al. The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics 2005; 5: 1520–1532.
63. Smith KR, Damiano J, Franceschetti S, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 2012; 90: 1102–1107.
64. Smith KR, Dahl HH, Canafoglia L, et al. Cathepsin F mutations cause type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet 2013; 22: 1417–1423.
65. Spielmeyer W. Über familiäre amaurotische Idiotien. Neurol Cb 1905; 24: 620–621.
66. Staropoli JF, Karaa A, Lim ET, et al. A homozygous mutation in links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system KCTD7. Am J Hum Genet 2012; 91: 202–208.
67. Steinfeld R, Reinhardt K, Schreiber K, et al. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet 2006; 78: 988–998.
68. Stengel OC. Beretnig om et maerkeligt Sygdomstilfaelde hos fire Sødskende I Nærheden af Roraas. Eyr 1826; 1: 347–352.
69. Topcu M, Tan H, Yalnizoglu D, et al. Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: clinical, neurophysiological, neuroradiological and histopathologic studies. Turk J Pediatr 2004; 46: 1–30.
70. Tyynela J, Suopanki J, Santavuori P, Baumann M, Haltia M. Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry. J Neuropathol Exp Neurol 1997; 56: 369–375.
71. Uvebrant P, Hagberg B. Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures. Neuropediatrics 1997; 28: 6–8.
72. Van Diggelen OP, Thobois S, Tilikete C, et al. Adult neuronal ceroid lipofuscinosis with palmitoyl-protein thioesterase deficiency: first adult-onset patients of a childhood disease. Ann Neurol 2001; 50: 269–272.
73. Vanhanen SL, Puranen J, Autti T, et al. Neuroradiological findings (MRS, MRI, SPECT) in infantile neuronal ceroid-lipofuscinosis (infantile CLN1) at different stages of the disease. Neuropediatrics 2004; 35: 27–35.
74. Vesa J, Hellsten E, Verkruyse LA, et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 1995; 376: 584–587.
75. Vogt H. Über familiäre amaurotische Idiotie und verwandte Krankheitsbilder. Monatsschr Psychiatr Neurol 1905; 18: 161–171.
76. Warrier V, Vieira M, Mole SE. Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses. Biochim Biophys Acta 2013; 1832: 1827–1830.
77. Whiting RE, Narfström K, Yao G, et al. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis. Exp Eye Res 2014; 125: 164–172.
78. Wisniewski KE, Connell F, Kaczmarski W, et al. Palmitoyl-protein thioesterase deficiency in a novel granular variant of LINCL. Pediatr Neurol 1998; 18: 119–123.
79. Wisniewski KE, Zhong N, Philippart M. Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology 2001; 57: 576–581.
80. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19: 463–474.